Breast Cancer Research

official impact factor 5.79
Search for
Advanced search
Breast Cancer Research
Tools
Correction

Correction: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

Trevor Powles1*, Alexander Paterson2, Eugene McCloskey3, Phil Schein4, Bobbi Scheffler5, Alwynne Tidy6, Sue Ashley6, Ian Smith6, Lars Ottestad7 and John Kanis3

Author Affiliations

1 Parkside Oncology, London, UK

2 Tom Baker Cancer Centre, Calgary, Alberta, Canada

3 WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK

4 Department of Clinical Pharmacology, University of Oxford, Oxford, UK

5 Scheffler Group, Villanova, Pennsylvania, USA

6 Royal Marsden Hospital, London, UK

7 Radium Institute, Oslo, Norway

For all author emails, please log on.

Breast Cancer Research 2006, 8:406 doi:10.1186/bcr1413


The electronic version of this article is the complete one and can be found online at: http://breast-cancer-research.com/content/8/3/406


Published:3 May 2006

© 2006 BioMed Central Ltd

Correction

It has been brought to our attention that there was a typographical error in our recent article [1] published in March 2006.

In the Conclusions section the final sentence should read:

Questions such as the optimal duration of therapy and efficacy in stage I disease remain to be answered.

References

  1. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026].

    Breast Cancer Research 2006, 8:R13. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL